Feasibility of extracorporeal elimination of liposomal chemotherapeutics by double membrane plasmapheresis - CARL-Studie

Trial Profile

Feasibility of extracorporeal elimination of liposomal chemotherapeutics by double membrane plasmapheresis - CARL-Studie

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Vinorelbine
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARL
  • Most Recent Events

    • 27 Dec 2012 Planned number of patients changed from 15 to 21 as reported by German Clinical Trials Register.
    • 27 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by German Clinical Trials Register.
    • 06 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top